XtalPi Partners with Janssen Biotech to Accelerate Biologics Discovery Using AI

• AI-driven firm XtalPi's division, Ailux Biologics, has signed a licensing deal with Janssen Biotech to use its XtalFold platform for biologics discovery.
• XtalFold uses AI to model biomolecular interactions, aiding in drug development, particularly for monoclonal antibodies and other biotherapeutics.

AI-driven drug discovery firm XtalPi has entered into a licensing agreement between its division, Ailux Biologics, and Janssen Biotech, Inc., a subsidiary of Johnson & Johnson. The agreement grants Janssen a non-exclusive license to utilize XtalPi’s proprietary XtalFold platform, an AI-based software designed to accelerate the discovery and engineering of biologics. The deal was facilitated by Johnson & Johnson Innovation.

XtalFold offers advanced modeling of biomolecular interactions using only sequence data, a capability crucial for developing biotherapeutics like monoclonal antibodies.

The platform has been benchmarked to perform at state-of-the-art levels, particularly in accurately modeling difficult regions such as antibody-antigen interfaces. Since its launch, XtalFold has been validated in more than 30 partner and internal programs, proving its efficacy in a range of applications, including antigen design, epitope identification, and bispecifics design.